5 results about "Collagen fibril" patented technology

A system for visualizing a target site in an eye using a polarization sensitive optical coherence tomography (PS-OCT) device includes a controller having at least one processor and at least one non-transitory tangible memory on which instructions are recorded. The target site is one or more vitreous opacity in vitreous fluid of the eye. The controller is configured to receive the PS-OCT data and determine, based on the PS-OCT data, at least one parameter corresponding to a birefringence characteristic of collagen fibrils in the vitreous humor. The at least one parameter includes a respective pitch of collagen fibrils. The controller is configured to determine a respective location of the one or more vitreous opacity when the at least one parameter exceeds a predefined range, and to generate a control signal adapted to direct the treatment beam at the respective location of the one or more vitreous opacity.

This invention relates to the field of congenital heart disease treatment technology, and discloses the application of sapropterin in the prevention and treatment of bisphenol fluorene-induced congenital heart disease in fetuses. The congenital heart disease includes cardiac structural defects, heart failure, or cardiomyocyte lesions, specifically selected from ventricular septal defects, atrial septal defects, tetralogy of Fallot, myocardial hypertrophy, decreased cardiac ejection fraction, decreased short-axis contraction rate, cardiomyocyte ferroptosis, myocardial tissue inflammatory infiltration, or myocardial collagen fibrosis. Sapropterin is used as a direct supplement to biological tetrahydropterin (BH4). Through exogenous intervention, it precisely reverses the endogenous BH4 deficiency caused by bisphenol fluorene exposure, restores the expression of GTP cyclase 1 (GCH1) and the dynamic balance of RNA m6A, and upregulates the level of YTH domain family protein 2 (YTHDF2), thereby blocking ferroptosis signal transduction, reducing oxidative stress and inflammatory response, and inhibiting the process of myocardial tissue fibrosis at the molecular level.

The present technique pertains to a method of preparation of a succinylated collagen-fibrinogen hydrogel and a succinylated collagen-fibrinogen hydrogel prepared thereby. The method of preparation of a succinylated collagen-fibrinogen hydrogel according to the present technique can produce a collagen-based bio-substance in a simple process, wherein collagen can be prevented from being entangled and an improvement can be brought about in hydrophilicity, cell growth rate, cell compatibility, and cell diffusion capability, whereby the collagen-based bio-substance exhibits excellent biocompatibility in vivo.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to application of herba artemisiae scopariae and an ethanol herba artemisiae scopariae extract in a medicine for treating autoimmune hepatitis, the ethanol herba artemisiae scopariae extract can reduce ALT and AST of a patient suffering from the autoimmune hepatitis, can effectively reverse liver tissue lesions of the patient suffering from the autoimmune hepatitis, and has the advantages that the curative effect is good, and the curative effect is good. The content of collagen fibrinogen in animal livers is reduced, so that hepatic fibrosis of patients with the autoimmune hepatitis is effectively reversed, proinflammatory factors TNF-alpha, IL-6 and IL-1beta in serum are reduced, the content of an anti-inflammatory factor IL-10 is increased, and the composition has a protective effect on inflammatory injury of liver tissues with the autoimmune hepatitis and can be used for treating the liver with the autoimmune hepatitis. And the content of serum immune globulins IgG and IgM can also be reduced. Through the effects, the oriental wormwood and the ethanol oriental wormwood extract can effectively improve autoimmune hepatitis.

Products, processes, compositions, kits, and methods are provided for cartilage-derived implants. The implants can exhibit resistance to enzyme (e.g., collagenase, protease, etc.) digestion compared to the source tissue from which they were derived while still having one or more mechanical properties comparable to the source tissue from which they were derived. The implants can also have a plurality of molecular bridges between molecules of the cartilaginous material. The molecular bridges can connect one or more collagen fibrils and / or / with one or more glycosaminoglycans. The implants can also be treated with cationic detergent, packaged and sterilized with or without additional components, and surgically implanted into subjects.